Ra’anana, Israel-based Inspira plans to debut the devices at the Extracorporeal Life Support Organization (ELSO) Conference in Seattle.
The line of devices includes the ART100 cardio-pulmonary bypass (CPB) device for patients undergoing CPB procedures. Additionally, the company has high hopes for its ART500 device.
Inspira says ART500 represents a significant breakthrough in healthcare with an effective treatment for people facing severe breathing problems. It provides acute respiratory support for patients who may require legacy mechanical ventilation.
The company submitted the ART100 device to the FDA earlier this month. It expects ART100 to receive FDA clearance in the first half of 2024. Inspira entered into a collaboration with Perfusion Solution in the U.S. as it looks to make the system available in the country.
ART500, which also remains investigational, could boost oxygen saturation levels in a matter of minutes, even with the patient staying awake. Inspira aims to deliver blood circulation technology with AI-driven monitoring nad analytics.
“Through our continuous efforts, we aim to reshape the future of extracorporeal treatments to create a better healthcare experience for patients around the world,” the company says.
